Breaking News Instant updates and real-time market news.

DCPH

Deciphera

$35.88

15.97 (80.21%)

07:15
08/14/19
08/14
07:15
08/14/19
07:15

Deciphera price target raised to $65 from $50 at Canaccord

Canaccord analyst Arlinda Lee raised her price target on Deciphera to $65 from $50 following positive topline Phase3 ripretinib 4L GIST data. The analyst said the results significantly met its primary endpoint and showed notable benefit in RR and OS. He views the data as highly competitive and views its proprietary kinase switch control-based pipeline as attractive. Lee reiterated her Buy rating on Deciphera shares.

  • 15

    Aug

DCPH Deciphera
$35.88

15.97 (80.21%)

08/13/19
PIPR
08/13/19
NO CHANGE
Target $55
PIPR
Overweight
Deciphera Phase 3 Invictus study a 'best-case' scenario, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond views this morning's Phase 3 Invictus study results from Deciphera Pharmaceuticals as a "best-case" scenario. A 27.6 week progression free survival measure was better than the un-adjudicated Phase 1 experience of 24 weeks, and was also statistically significant improved versus placebo, Raymond tells investors in a research note. While some may quibble with a non-statistically significant overall response rate, this "misses the broader point, which is that ripretinib is now not just approvable, but in our view very likely the best-in-class KIT inhibitor" in gastrointestinal stromal tumors, says Raymond. He expects Deciphera shares to "rally sharply" today and keeps an Overweight rating on the name with a $55 price target. The stock in premarket trading is up 122%, or $24.40, to $44.35.
08/13/19
GUGG
08/13/19
NO CHANGE
Target $66
GUGG
Buy
Deciphera price target raised to $66 from $44 at Guggenheim
Guggenheim analyst Michael Schmidt raised his price target on shares of Deciphera to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study.
08/13/19
08/13/19
NO CHANGE
Target $68

Buy
Deciphera INVICTUS results best-case scenario, price target raised at Guggenheim
As previously reported, Guggenheim analyst Michael Schmidt raised his price target for Deciphera (DCPH) to $66 from $44 after the company announced top-line results from the Phase 3 INVICTUS study of ripretinib in 4L+ GIST, which he believes "significantly exceeded" investors' expectations and validated his bullish thesis and analyses heading into the binary event. The analyst notes that results included a 6.3 months mPFS readout in a setting with no approved therapies and also compare favorably to competitor data from Blueprint Medicines (BPMC) in similar patients. Together with updated Phase 1 ripretinib data across 2L and 3L GISTs, Schmidt thinks these results read-through positively also for the drug's potential in earlier stage GIST patients. Deciphera's Phase 3 INTRIGUE trial in 2L GIST will complete enrolling in the second quarter of 2020, he adds. The analyst has a Buy rating on Deciphera's shares.
08/13/19
DBAB
08/13/19
NO CHANGE
DBAB
Buy
Deciphera price target raised to $66 after cancer data at Deutsche Bank
Deciphera Pharmaceuticals in late morning trading is up 97%, or $19.32, to $39.27.

TODAY'S FREE FLY STORIES

RTRX

Retrophin

$13.58

-3.815 (-21.94%)

15:23
08/22/19
08/22
15:23
08/22/19
15:23
Recommendations
Retrophin analyst commentary  »

Retrophin price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPS

Gap

$17.69

0.73 (4.30%)

15:19
08/22/19
08/22
15:19
08/22/19
15:19
Options
Gap options imply 18.9% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 25

    Sep

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/22/19
08/22
15:17
08/22/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLSD

Clearside Biomedical

$0.78

-0.485 (-38.34%)

15:16
08/22/19
08/22
15:16
08/22/19
15:16
Recommendations
Clearside Biomedical analyst commentary  »

Clearside Biomedical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/22/19
08/22
15:16
08/22/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ISCA

International Speedway

$45.07

(0.00%)

15:11
08/22/19
08/22
15:11
08/22/19
15:11
Hot Stocks
International Speedway announces resignation of COO Joie Chitwood »

International Speedway…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KKR

KKR

$25.75

0.05 (0.19%)

15:09
08/22/19
08/22
15:09
08/22/19
15:09
Periodicals
KKR looking into sale of Epicor Software, Reuters reports »

KKR is looking into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPQ

HP Inc.

$18.96

0.01 (0.05%)

15:04
08/22/19
08/22
15:04
08/22/19
15:04
Options
HP Inc. options imply 9.7% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 10

    Sep

KKR

KKR

$25.74

0.04 (0.16%)

15:00
08/22/19
08/22
15:00
08/22/19
15:00
Periodicals
Breaking Periodicals news story on KKR »

KKR looking into sale of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$147.63

0.23 (0.16%)

14:49
08/22/19
08/22
14:49
08/22/19
14:49
Options
Salesforce options imply 8.6% move in share price post-earnings »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

MYGN

Myriad Genetics

$23.88

-1.24 (-4.94%)

14:44
08/22/19
08/22
14:44
08/22/19
14:44
Recommendations
Myriad Genetics analyst commentary at Piper Jaffray »

LCD's incrementally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 13

    Nov

PINC

Premier

$37.88

0.1 (0.26%)

14:36
08/22/19
08/22
14:36
08/22/19
14:36
Recommendations
Premier analyst commentary at Piper Jaffray »

Piper says Premier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 20

    Nov

CAH

Cardinal Health

$43.87

0.31 (0.71%)

14:35
08/22/19
08/22
14:35
08/22/19
14:35
Options
Cardinal Health put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MO

Altria Group

$46.24

-0.01 (-0.02%)

14:30
08/22/19
08/22
14:30
08/22/19
14:30
Hot Stocks
Altria Group raises quarterly dividend to 84c per share from 80c »

Altria Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$204.11

0.27 (0.13%)

, ALXN

Alexion

$125.28

10.41 (9.06%)

14:29
08/22/19
08/22
14:29
08/22/19
14:29
On The Fly
Analyst says rumored Amgen bid for Alexion 'could make a ton of sense' »

After Spanish publication…

AMGN

Amgen

$204.11

0.27 (0.13%)

ALXN

Alexion

$125.28

10.41 (9.06%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 02

    Sep

  • 06

    Sep

  • 09

    Sep

  • 16

    Sep

  • 19

    Sep

  • 02

    Oct

  • 19

    Oct

  • 04

    Nov

FL

Foot Locker

$41.82

2.06 (5.18%)

, HIBB

Hibbett Sports

$17.04

0.88 (5.45%)

14:29
08/22/19
08/22
14:29
08/22/19
14:29
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

FL

Foot Locker

$41.82

2.06 (5.18%)

HIBB

Hibbett Sports

$17.04

0.88 (5.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Aug

  • 23

    Aug

  • 19

    Sep

  • 25

    Sep

CRM

Salesforce

$147.66

0.26 (0.18%)

, INTU

Intuit

$276.18

-0.16 (-0.06%)

14:28
08/22/19
08/22
14:28
08/22/19
14:28
Earnings
Notable companies reporting after market close »

Notable companies…

CRM

Salesforce

$147.66

0.26 (0.18%)

INTU

Intuit

$276.18

-0.16 (-0.06%)

VMW

VMware

$147.20

-0.84 (-0.57%)

ROST

Ross Stores

$107.05

1.37 (1.30%)

HPQ

HP Inc.

$18.95

(0.00%)

GPS

Gap

$17.58

0.62 (3.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 10

    Sep

  • 25

    Sep

  • 10

    Oct

  • 27

    Oct

  • 12

    Dec

  • 16

    Dec

SPLK

Splunk

$117.83

-10.68 (-8.31%)

14:24
08/22/19
08/22
14:24
08/22/19
14:24
Recommendations
Splunk analyst commentary at BMO Capital »

BMO Capital remains…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Aug

  • 15

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/22/19
08/22
14:17
08/22/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/22/19
08/22
14:16
08/22/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WLL

Whiting Petroleum

$8.41

-0.28 (-3.22%)

14:15
08/22/19
08/22
14:15
08/22/19
14:15
Options
Whiting Petroleum put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 08

    Oct

  • 09

    Oct

14:15
08/22/19
08/22
14:15
08/22/19
14:15
General news
Breaking General news story  »

Minneapolis Federal…

NWS

News Corp

$14.48

0.02 (0.14%)

, NWSA

News Corp.

$14.17

0.07 (0.50%)

14:12
08/22/19
08/22
14:12
08/22/19
14:12
Periodicals
News Corp prepares news app to address concerns with Google, Facebook, WSJ says »

News Corp (NWSA) is…

NWS

News Corp

$14.48

0.02 (0.14%)

NWSA

News Corp.

$14.17

0.07 (0.50%)

GOOG

Alphabet

$1,191.47

0.68 (0.06%)

GOOGL

Alphabet Class A

$1,192.10

1.84 (0.15%)

FB

Facebook

$181.72

-1.84 (-1.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 23

    Sep

  • 24

    Sep

  • 27

    Oct

AMZN

Amazon.com

$1,815.98

-7.21 (-0.40%)

14:00
08/22/19
08/22
14:00
08/22/19
14:00
Periodicals
Amazon acquires 49% interest in India's Future Coupons, TechCrunch reports »

Amazon has acquired a 49%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

BTHE

Boston Therapeutics

$0.00

(0.00%)

13:56
08/22/19
08/22
13:56
08/22/19
13:56
Hot Stocks
Boston Therapeutics BTI320 Phase 2 study achieves full enrollment »

Boston Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.